These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 30043746)

  • 1. PEPFAR at 15 years.
    Webster P
    Lancet; 2018 Jul; 392(10143):200. PubMed ID: 30043746
    [No Abstract]   [Full Text] [Related]  

  • 2. Estimating the impact of the US President's Emergency Plan for AIDS Relief on HIV treatment and prevention programmes in Africa.
    Heaton LM; Bouey PD; Fu J; Stover J; Fowler TB; Lyerla R; Mahy M
    Sex Transm Infect; 2015 Dec; 91(8):615-20. PubMed ID: 26056389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond indicators: advances in global HIV monitoring and evaluation during the PEPFAR era.
    Porter LE; Bouey PD; Curtis S; Hochgesang M; Idele P; Jefferson B; Lemma W; Myrick R; Nuwagaba-Biribonwoha H; Prybylski D; Souteyrand Y; Tulli T
    J Acquir Immune Defic Syndr; 2012 Aug; 60 Suppl 3():S120-6. PubMed ID: 22797733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expanding role of civil society in the global HIV/AIDS response: what has the President's Emergency Program For AIDS Relief's role been?
    Coutinho A; Roxo U; Epino H; Muganzi A; Dorward E; Pick B
    J Acquir Immune Defic Syndr; 2012 Aug; 60 Suppl 3():S152-7. PubMed ID: 22797737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PEPFAR, health system strengthening, and promoting sustainability and country ownership.
    Palen J; El-Sadr W; Phoya A; Imtiaz R; Einterz R; Quain E; Blandford J; Bouey P; Lion A
    J Acquir Immune Defic Syndr; 2012 Aug; 60 Suppl 3():S113-9. PubMed ID: 22797732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PEPFAR scale-up of pediatric HIV services: innovations, achievements, and challenges.
    Abrams EJ; Simonds RJ; Modi S; Rivadeneira E; Vaz P; Kankasa C; Tindyebwa D; Phelps BR; Bowsky S; Teasdale CA; Koumans E; Ruff AJ
    J Acquir Immune Defic Syndr; 2012 Aug; 60 Suppl 3(Suppl 3):S105-12. PubMed ID: 22797731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PEPFAR's evolving HIV prevention approaches for key populations--people who inject drugs, men who have sex with men, and sex workers: progress, challenges, and opportunities.
    Needle R; Fu J; Beyrer C; Loo V; Abdul-Quader AS; McIntyre JA; Li Z; Mbwambo JK; Muthui M; Pick B
    J Acquir Immune Defic Syndr; 2012 Aug; 60 Suppl 3():S145-51. PubMed ID: 22797736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the public-private mix: how economics can contribute to tuberculosis control.
    Sutton BS
    Expert Rev Anti Infect Ther; 2010 May; 8(5):489-91. PubMed ID: 20455675
    [No Abstract]   [Full Text] [Related]  

  • 9. Scale-up of HIV treatment through PEPFAR: a historic public health achievement.
    El-Sadr WM; Holmes CB; Mugyenyi P; Thirumurthy H; Ellerbrock T; Ferris R; Sanne I; Asiimwe A; Hirnschall G; Nkambule RN; Stabinski L; Affrunti M; Teasdale C; Zulu I; Whiteside A
    J Acquir Immune Defic Syndr; 2012 Aug; 60 Suppl 3(Suppl 3):S96-104. PubMed ID: 22797746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. District Health Officer Perceptions of PEPFAR's Influence on the Health System in Uganda, 2005-2011.
    Lohman N; Hagopian A; Luboga SA; Stover B; Lim T; Makumbi F; Kiwanuka N; Lubega F; Ndizihiwe A; Mukooyo E; Barnhart S; Pfeiffer J
    Int J Health Policy Manag; 2017 Feb; 6(2):83-95. PubMed ID: 28812783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of epidemiological data to inform the PEPFAR response.
    Lyerla R; Murrill CS; Ghys PD; Calleja-Garcia JM; DeCock KM
    J Acquir Immune Defic Syndr; 2012 Aug; 60 Suppl 3():S57-62. PubMed ID: 22797741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. US boosts disease surveillance effort.
    Dickey C
    Nat Med; 1998 Jan; 4(1):9. PubMed ID: 9427590
    [No Abstract]   [Full Text] [Related]  

  • 13. Creating a national culture of quality: the Tanzania experience.
    Mwidunda PE; Eliakimu E
    AIDS; 2015 Jul; 29 Suppl 2():S175-7. PubMed ID: 26102628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strengthening the fight against infectious disease.
    Public Health Rep; 2002; 117(6):591. PubMed ID: 12599362
    [No Abstract]   [Full Text] [Related]  

  • 15. How PEPFAR's public-private partnerships achieved ambitious goals, from improving labs to strengthening supply chains.
    Sturchio JL; Cohen GM
    Health Aff (Millwood); 2012 Jul; 31(7):1450-8. PubMed ID: 22778334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PEPFAR Transitions to Country Ownership: Review of Past Donor Transitions and Application of Lessons Learned to the Eastern Caribbean.
    Vogus A; Graff K
    Glob Health Sci Pract; 2015 Jun; 3(2):274-86. PubMed ID: 26085023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the impact of a 20% funding cut in international HIV aid from the United States?
    Ten Brink D; Martin-Hughes R; Kelly SL; Wilson DP
    AIDS; 2019 Jul; 33(8):1406-1408. PubMed ID: 31157667
    [No Abstract]   [Full Text] [Related]  

  • 18. Progress in public-private partnerships to fight neglected diseases.
    Gustavsen K; Hanson C
    Health Aff (Millwood); 2009; 28(6):1745-9. PubMed ID: 19887415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using economic analysis to improve tuberculosis control.
    Miller TL; Weis SE
    Int J Tuberc Lung Dis; 2009 Jun; 13(6):671. PubMed ID: 19460241
    [No Abstract]   [Full Text] [Related]  

  • 20. Civil society perspectives on negative biomedical HIV prevention trial results and implications for future trials.
    Essack Z; Koen J; Slack C; Lindegger G; Newman PA
    AIDS Care; 2012; 24(10):1249-54. PubMed ID: 22360605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.